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The imidazoquinolineamine derivative 1-(2-methyl propyl)-1H-imidazole [4,5-c]quinoline-4-amine (imi-
quimod) has been shown to induce alpha interferon (IFN-a) synthesis both in vivo and in peripheral blood
mononuclear cells in vitro. In this study, we show that, in these cells, imiquimod induces expression of several
IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the
expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. Expression of all these genes was
transient, independent of cellular protein synthesis, and inhibited in the presence of tyrosine kinase and
protein kinase C inhibitors. Infection with Sendai virus led to expression of a similar set of cytokine genes and
several of the IFNA genes. Imiquimod stimulates binding of several induction-specific nuclear complexes: (i)
the NF-kB-specific complexes binding to the kB enhancer present in the promoters of all cytokine genes, but
not in IFNA genes, and (ii) the complex(es) binding to the A4F1 site, 5*-GTAAAGAAAGT-3*, conserved in the
inducible element of IFNA genes. These results indicate that imiquimod, similar to viral infection, stimulates
expression of a large number of cytokine genes, including IFN-a/b, and that the signal transduction pathway
induced by both of these stimuli requires tyrosine kinase and protein kinase activity.
The low-molecular-weight imidazoquinolineamine deriva-
tive 1-(2-methyl propyl)-1H-imidazole [4,5-c]quinoline-4-amine
(imiquimod) inhibits replication of herpes simplex virus type 2
and cytomegalovirus in infected guinea pigs (6, 24). Imiquimod-
mediated inhibition of virus replication is related to its ability to
induce interferon (IFN). Oral administration of imiquimod in-
duces IFN-a in mice, rats, guinea pigs, monkeys, and humans.
(New approved nomenclature for IFN genes [9a] is used through-
out this paper.) In addition to having antiviral activity, imiquimod
was shown to inhibit growth of several transplantable murine
tumors, including MC-26 colon carcinoma and Lewis lung carci-
noma (71). The induction of IFN-a plays a major, but not exclu-
sive, role in this growth inhibition, since an antiserum to mouse
IFN-a and IFN-b significantly reduced the antitumor effect of
imiquimod but was not able to abolish it completely.
IFN-a proteins are represented by a large family of struc-
turally related genes which show about 94% homology at the
nucleotide level, while IFN-b is encoded by a single gene.
IFNA genes are expressed preferentially in cells of lymphoid
lineage, and the individual subtypes show cell-type-specific dif-
ferences in expression (2, 29, 35), while IFNB is expressed in a
large variety of cells. The biological significance of the large
abundance of IFNA genes is not clear; all IFN-a and IFN-b
subtypes show antiviral and antitumor properties and seem to
bind to a common receptor (39); however, some differences
between their immunomodulatory effects have been reported
(21, 56).
Virus-induced expression of IFNA and IFNB genes is medi-
ated by a virus-responsive element (VRE) present in the pro-
moters of IFNA and IFNB genes that, by itself, functions as a
virus-specific enhancer and can confer inducibility in infected
cells (3, 14, 19, 20, 58, 65). At least two families of transcrip-
tional factors were shown to play a role in induction of IFN
genes that have binding sites within the VRE. One family is the
set of IFN-responsive factors IRF-1 and IRF-2, which function
as activator and repressor, respectively (22, 23). Overexpres-
sion of these two factors can regulate activity of both IFNA and
IFNB promoter regions in a transient expression assay; a single
nucleotide mutation in the IRF-1 binding site of the murine
IFNA4 gene promoter decreased inducibility by about 100-fold
(2), and cells expressing IRF-1 antisense mRNA were unable
to express IFNB genes (62). However, the role of IRF-1 in
induction of the IFN gene has been questioned, since deletion
of the IRF-1 gene did not affect virus-mediated inducibility of
IFN genes either in mice in vivo or in cultured cells in vitro (53,
64). The second family of transcriptional factors are the kB-
specific binding proteins that play a role in activation of the
IFNB gene (16, 19, 28, 43, 77), and recently, a direct role of
IFN-induced double-stranded RNA (dsRNA)-dependent ki-
nase in activation of NF-kB has been shown (37, 49). Further-
more, it was shown that HMG I(Y) and ATF-2 can bind to the
VRE (48, 75) of the IFNB gene, where HMG I(Y) proteins
appear to bend the DNA and facilitate binding of both NF-kB
and ATF-2.
Factors involved in the regulation of IFNA genes other than
IRF-1 are less well-defined. Two proteins of 68 and 96 kDa
were found to bind the A4F1 regulatory element in the VRE of
the murine IFNA4 gene promoter (1, 2), and MacDonald et al.
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(47) described a factor (named TG) that binds to the VRE of
the human IFNA1 gene. These proteins, however, have not yet
been characterized.
The signal transduction pathway, triggered by viral infection
that activates these factors and leads to the induction of IFN
genes, is not known. Earlier studies have suggested that the
dsRNA formed as an intermediate product during replication
of RNA viruses is essential for the stimulation of expression of
IFN genes (32, 50). This assumption was based on the follow-
ing observations. First, there is a difference in the IFN-induc-
ing capacities of plus- and minus-stranded RNA viruses. In-
fectivity of plus-stranded viruses is essential for IFN induction,
while the ability of UV-irradiated minus-stranded viruses to
induce IFN correlated with their ability to transcribe their
genome and produce complementary RNA (26, 46). Second,
D1 particles of vesicular stomatitis virus containing covalently
linked complementary message and antimessage RNA are very
effective IFN inducers (51) and dsRNA, such as poly(rI) z
poly(rC), alone is able to induce expression of the IFNB gene
(11). Third, DNA viruses that do not form dsRNA during the
replication cycle are not effective inducers of IFN (30). However,
in lymphocytes, expression of the Sendai virus C gene was suffi-
cient to induce IFN (74), and viral glycoproteins or nucleic acid-
free viral envelopes were also able to induce IFN production in
peripheral blood mononuclear cells (PBMC) (12, 33, 40, 42, 81).
Thus, the role of dsRNA as an essential trigger for IFN induction
remains questionable.
The aim of the proposed study was to analyze the molecular
mechanism by which imiquimod (R-837) stimulates IFN syn-
thesis in PBMC in vitro, to determine the responsive cell
type(s), and to identify the expressed IFN subtypes. The results
show that imiquimod stimulates expression of IFNA1, IFNA2,
IFNA5, IFNA6, and IFNA8 genes as well as IFNB in PBMC
and that IFN synthesis can be detected in B cells and mono-
cytes/macrophages. In addition to inducing expression of IFN
genes, imiquimod also induced expression of tumor necrosis
factor alpha (TNF-a), interleukin-6 (IL-6), and IL-8 genes;
expression of all these genes was transient, independent of
cellular protein synthesis, and inhibited by tyrosine kinase
(TK) and protein kinase C (PKC) inhibitors.
MATERIALS AND METHODS
Isolation of different populations of leukocytes. Human PBMC were isolated
from Leukopack platelets by density gradient centrifugation in lymphocyte sep-
aration medium (LSM) (Organon Teknika Corp., Durham, N.C.) (4). The cells
were further separated on the basis of their adherence to plastic surfaces (36). To
determine the type of cells responsible for IFN production, B cells, T cells, and
monocytes were isolated either by sorting with a fluorescence-activated cell
sorter (FACS) or by indirect rosetting with Dynabeads. T and B lymphocytes
were separated by FACS from the nonadherent population of human PBMC
after being stained with anti-Leu-4 (CD3) and anti-Leu-12 (CD19) monoclonal
antibodies, respectively (Simultest T and B Cell Test; Becton-Dickinson). For
separation by magnetic beads, T cells and B cells were first isolated from the
nonadherent fraction of PBMC by rosetting with sheep erythrocytes as described
elsewhere (13). T cells were then isolated by positive selection with anti-CD3
monoclonal antibody and incubated with anti-mouse-immunoglobulin G (IgG)-
coated Dynabeads. B cells consisted of a population of a nonadherent, E-rosette-
negative fraction of PBMC that did not form rosettes with the anti-mouse-IgG-
coated dynabeads after treatment with anti-CD3 and anti-CD14 murine
monoclonal antibodies. Monocytes were isolated from a fraction of human
PBMC that adhered (after 15 min) to plastic by staining with anti-CD14 mouse
monoclonal antibody and selection with anti-mouse-IgG-coated Dynabeads. For
induction, 5 3 106 PBMC, monocytes, or nonadherent cells per ml and 5 3 104
separated cells per ml were used. Cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 2 mM L-glutamine.
PCR analysis. Two sets of oligonucleotide primers corresponding to sequences
of human IFNA genes were used (25). A pair of primers designed to recognize
all of the IFNA subtypes had the following sequences: 59 primer, GTACTGCA
GAATCTCTCCTTTCTCCTG (nucleotides [nt] 11067 to 1086); 39 primer, GT
GTCTAGATCTGACAACCTCCCAGGGCACA (nt 11415 to 1435). The sec-
ond set of primers was specific for IFNA2 and had the following sequences: 59
primer, GTACTGCAGCATCTGCAACATCTAC (nt 1911 to 930); 39 primer,
GTGTCTAGAGTCTTTGAAATGGCAG (nt 11565 to 1582). The general
primers, selected from a highly conserved region of the IFNA genes (see Fig. 4),
amplified a 369-bp fragment, while the IFNA2-specific primers amplified a
672-bp product corresponding predominantly to IFNA2 mRNA. Each primer
contained either a PstI (59 primer) or an XbaI (39 primer) restriction sequence
that facilitated its cloning. The sequences of the restriction sites are underlined;
a single line represents the PstI site, and a double line represents the XbaI site.
In the reverse transcription (RT)-PCR analysis, first-strand synthesis (cDNA)
was carried out in 50 mM Tris-HCl (pH 8.3)–140 mM KCl–10 mMMgCl2–4 mM
dithiothreitol (DTT)–1 mM each deoxynucleoside triphosphate (dNTP mix)–20
U of RNase inhibitor (Life Technologies, Inc.)–1.25 U of avian myeloblastosis
virus reverse transcriptase (Life Technologies, Inc.)–1 mg of oligo(dT) (Sigma).
The reaction mixture (25 ml) was incubated at 428C for 2 h. Next, 1/10 of the
cDNA mixture was amplified in 50 mM KCl–10 mM Tris-HCl (pH 8.3)–1.5 mM
MgCl2–0.01% (wt/vol) gelatin–200 mM dNTP mix–200 mg of each primer–2.5 U
of TaqDNA polymerase (Boehringer Mannheim, Indianapolis, Ind.) in a volume
of 50 ml by use of an automated thermocycler (Perkin-Elmer Cetus, Norwalk,
Conn.). Reaction mixtures were heated to 948C for 4 min and subjected to 30
amplification cycles, each consisting of three rounds at 94, 50, and 728C, respec-
tively, for 1 min each followed by a final extension for 5 min at 728C. As a control,
amplifications were done in a reaction mixture without first-strand cDNA. Am-
plified fragments were either digested with the appropriate restriction endo-
nucleases to identify the fragment amplified or ligated to pGEM4.
DNA sequencing. Sequencing of dsDNA was done by the dideoxy chain-
terminating method (68) with a Sequenase kit (United States Biochemical Corp.)
and SP6 and T7 primers.
RNA and DNA probes. IFNA riboprobe was prepared by insertion of a 764-bp
EcoRI-BglII fragment of human IFNA2 cDNA (55) into pSP64 followed by
cloning. The plasmid was linearized with EcoRI, and RNA was transcribed by
SP6 polymerase. The IFNB probe was prepared by insertion of a 520-bp frag-
ment of human IFNB cDNA (60) into pSP64, and the plasmid was linearized
with EcoRI. The IL-6 probe was prepared by insertion of a 550-bp PstI fragment
of human IL-6 cDNA into pSP64 vector, followed by linearization with EcoRI.
IRF-1 probe was prepared by ligation of a 460-bp BglI-EcoRI fragment of human
IRF-1 cDNA into theHincII site of pSP65 and linearization withHindIII. TNF-a
probe was represented by an 800-bp EcoRI fragment of human TNF-a cDNA in
Bluescript SK vector; after linearization with BamHI, RNA was transcribed with
T7 polymerase. Human g-actin cDNA in pSP64 vector was linearized with HinfI.
All transcribed RNAs were radiolabelled with [a-32P]GTP as described previ-
ously (1). pTZ/IL-8 plasmid was digested with PstI, and the ;400-bp cDNA
insert was purified and labelled with [a-32P]dCTP (Pharmacia) by random priming.
Northern (RNA) blot analysis. Human PBMC (107 per cell sample) were
stimulated with 3 mg of imiquimod per ml or infected with Sendai virus for
various times; control cultures incubated in parallel were left untreated. Total
cellular RNA was prepared by the guanidine thiocyanate method (7), and 10 mg
was denatured in 50% deionized formamide–2.2 M formaldehyde–20 mM
MOPS (morpholinepropanesulfonic acid) for 15 min at 608C and chilled on ice.
RNA was then fractionated by electrophoresis in 0.8% agarose gels containing
2.2 M formaldehyde and 20 mM MOPS and subsequently blotted onto nitrocel-
lulose filters with 203 SSC (13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate).
Prehybridization and hybridization with single-stranded riboprobes or dsDNA
probes were performed at 60 and 458C, respectively, in a buffer containing 50%
formamide, 0.1% sodium dodecyl sulfate (SDS), 53 SSC, 13 Denhardt’s solu-
tion, 50 mM potassium phosphate buffer (pH 6.6), and 0.25 mg of denatured
salmon sperm DNA per ml. After hybridization, filters were washed with 0.1%
SDS–0.53 SSC at 60 or 458C and exposed to Kodak XAR-5 film with intensifying
screens at2708C. Blots were stripped for sequential hybridization by boiling with
0.13 SSC–0.1% SDS for 15 min.
Preparation of nuclear extracts. Nuclear extracts were prepared as described
previously (2), and specific protein-DNA complexes were detected by a gel
mobility shift assay (2). Briefly, each cell pellet was resuspended in buffer A (10
mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid [HEPES] [pH 7.9], 1.5
mM MgCl2, 10 mM KCl, 0.3 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride
[PMSF], and 0.5% Nonidet P-40) and incubated at 48C. Nuclei were collected by
centrifugation, resuspended in buffer C (20 mM HEPES [pH 7.9], 25% glycerol,
500 mMKCl, 1.5 mMMgCl2, 0.2 mM EDTA, 0.5 mMDTT, 0.5 mM PMSF), and
incubated for 30 min at 48C. After centrifugation at 15,000 rpm in a Tomy
MTX-150 microcentrifuge, the supernatant fraction was dialyzed against buffer
D (20 mM HEPES [pH 7.9], 50 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM
DTT, 0.5 mM PMSF) and stored at 2708C.
Preparation of radiolabelled oligonucleotides and electrophoretic mobility
shift assays.Double-stranded oligonucleotide spanning the NF-kB site of human
immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) (59-
TCAAGGGACTTTCCGCTGGGACTTTCCCTCTCCTT-39) (78) was used for
DNA binding studies. The underlined sequence was used for annealing of a
primer, GGGAGAGGAA, and synthesis of the complementary strand with
Klenow polymerase labelled with [32P]dCTP. Protein-DNA complexes were
formed by incubation of 5 to 10 mg of nuclear protein with 1 to 10 pg of
radiolabelled DNA probe at 48C for 5 min in a 25-ml reaction volume containing
12 mM Tris (pH 7.6), 100 mM KCl, 0.1 mM EDTA, 0.5 mM DTT, 5 mM MgCl2
2 mg of poly(dI) z poly(dC) per ml, and 7% glycerol. For supershift experiments,
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serum containing antibodies against p65, p50, or c-rel was added to the prein-
cubated DNA-protein binding mixture and then the mixture was incubated for
1 h on ice.
The sequences of A4F1 (2) and PRDI (48) used as probes were 59-GCGTA
AAGAAAGTCCCTCTCCTT and 59-GAGAAGTGAAAGTGGGAACCCTC
TCCTT, respectively; the primer-annealing sequence is underlined. The 32P-
labelled double-stranded probes were prepared by extension of the primer with
Klenow polymerase and [32P]dCTP. The binding mixture was identical to that
described above.
Protein-DNA complexes were resolved by electrophoresis on 4% nondenatur-
ing polyacrylamide gels in 0.43 Tris-borate-EDTA, pH 8.3, at 150 V for 2 h at
room temperature. Gels were dried and exposed to Kodak X-ray film.
UV cross-linking in situ. Nuclear proteins were bound to a probe (A4IE) that
corresponds to the virus-inducible element of the IFNA4 gene promoter region
containing the A4F1 and IRF-1 binding sequences (2) substituted with 59-bromo-
29-deoxyuridine (BrdUrd) (Boehringer-Mannheim) and labelled with Klenow
polymerase and [32P]dCTP. The DNA-protein complex was resolved on a 4%
nondenaturing polyacrylamide gel and UV irradiated in situ for 10 min at 48C (2,
78). The UV-cross-linked DNA-protein adduct was then eluted and separated on
an SDS–10% acrylamide gel.
RESULTS
Induction of IFN in human PBMC. To determine the kinet-
ics of IFN production in human PBMC, cells were induced
with 3 mg of imiquimod per ml for different periods of time.
The applied dose was found to be optimal in a dose-response
experiment (data not shown). Imiquimod induced rapid and
transient IFN production, with the highest yield between 3 and
5 h after induction (Table 1). In contrast, the maximal response
to Sendai virus infection was observed between 10 and 12 h
postinduction (data not shown) and synthesis proceeded for
about 24 h (Table 1 and data not shown). The IFN was iden-
tified as human IFN-a by serologic characterization, since 98%
of the antiviral activity was neutralized by antibodies to human
IFN-a. In addition to inducing IFN, both imiquimod and Sen-
dai virus induced high levels of IL-6 (6,400 U at 4 h).
Identification of the cell types producing IFN-a. To evaluate
the phenotype of the IFN-producing cells in human PBMC, we
initially separated PMBC into a population of cells that ad-
hered to plastic (the majority of cells are monocytes) and those
that were nonadherent (predominantly B and T cells) and
found that both these cell populations produced IFN-a after
exposure to imiquimod. We therefore further purified B cells,
T cells, and monocytes by FACS sorting or indirect rosetting
with dynabeads as described in Materials and Methods. Sepa-
rated cells were induced with imiquimod or Sendai virus, and
medium was assayed for IFN activity (Table 2). Both Sendai
virus and imiquimod induced IFN synthesis in B cells and
monocytes but not in T cells. Thus, for the producer cell types,
there was no difference between Sendai virus and imiquimod.
Imiquimod-induced expression of IFNA, IFNB, TNF-a, IL-6,
IL-8, and IRF-1 mRNAs. We further examined the effect of
imiquimod treatment on expression of IFN genes and analyzed
the relative levels of IFNA and IFNB mRNAs in stimulated
cells. The results of Northern blot analysis are shown in Fig. 1.
Stimulation with imiquimod led to a significant increase in the
relative levels of IFNA and IFNB mRNAs as early as 2 h after
induction, while at 6 h poststimulation IFNA and IFNB
mRNAs were undetectable. Although we did not detect IFN-b
protein, Northern blot analysis revealed the presence of IFNB
mRNA in induced cells. IFNB mRNA was stabilized in the
presence of cycloheximide (CHX) as described previously (60,
61) (Fig. 1). Expression of the IFNB gene without detectable
secretion of the IFN-b protein has previously been found to
occur in Sendai virus-induced Namalwa cells (59, 70).
Imiquimod stimulation of PMBC also increased the relative
levels of TNF-a, IL-6, and IL-8. Expression of all these genes
was transient, reaching a maximum between 2 and 4 h after
induction and decreasing to baseline levels at 24 h. Expression
of the transcription factor IRF-1, which is induced by viral
infection, showed slower kinetics; maximal levels of IRF-1
mRNA were detected at 4 h after induction, and expression did
not return to baseline levels over 12-h period. It has been
shown that both TNF-a and IFNs induce expression of IRF-1
mRNA (15); thus, the prolonged increase in IRF-1 levels ob-
served may be mediated by the cytokines induced by imi-
quimod. Imiquimod-stimulated expression of all these cytokine
genes did not require ongoing protein synthesis, and increased
levels of the respective cytokine mRNAs could be detected in
CHX-treated cells. CHX was previously shown to increase the
rate of IFNB transcription by interfering with synthesis of the




cells at 16 h
Amt of IFN (U/ml) induced by imiquimod at:
0 h 2 h 3 h 4 h 5 h 9 h 24 h
Unseparateda 5 3 103 ,2 ,2 160 NDb 1,280 192 2
Monocytes 8 3 103 ,2 ,2 8 ND 16 6 16
Nonadherent 6 3 103 ,2 16 2,048 640 256 128 28
CD141 monocytesc 256 6 6
CD181 B cellsa 128 32
CD31 T cellsa ,4 ,4
a 5 3 106 cells per ml were used for stimulation.
b ND, not done.
c Cells were separated by FACS; separation with Dynabeads gave similar results. 5 3 104 cells per 100 ml were used for stimulation.
TABLE 2. Induction of IFN-a in different cell types
Selection method and cell typea




Monocytes (CD141) 14 64
B cells (CD191) 16 128
T cells (CD31) ,2 ,2
Dynabead selection
Monocytes (CD141) (adherent) 6 256
B cells (CD32 CD142) (nonadherent,
E-rosette negative)
32 ND
T cells (CD31) (nonadherent, E-rosette
positive)
,4 ,4
a 5 3 104 separated cells were used for induction; uninduced cells produced
less than 4 U of control activity per ml.
b Antiviral activity was abolished by treatment with antibodies to human
IFN-a.
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transcriptional repressor (34) as well as activating NF-kB (p50-
p65 complex) (27, 69), which may lead to increased transcrip-
tion of TNF-a, IL-6, and IL-8 genes, as well as IFNB. Further-
more, the posttranscriptional effect of CHX, which occurs at
the level of mRNA stabilization, was demonstrated for IFNB
and TNF-a (45, 60).
Induction of IFN genes and various cytokine genes in Sendai
virus-infected PBMC was analyzed as a control. Sendai virus
induced expression of all these cytokine genes; however, two
major differences between imiquimod and Sendai virus were
observed: (i) Sendai virus-induced expression of these genes
was slow; maximal increases in the IFNA and IFNB mRNA
levels occurred at 4 and 6 h postinfection, respectively; and (ii)
Sendai virus was a more effective inducer of all cytokine genes,
except the IL-8 gene, which was induced more effectively by
imiquimod.
The levels of IFNA and IFNBmRNAs were further analyzed
with stimulated populations of adherent cells enriched with
monocytes and macrophages and nonadherent cells containing
mostly T and B cells. A significant increase in the relative levels
of IFNA and IFNB mRNAs after imiquimod treatment was
observed to occur in both imiquimod-stimulated and Sendai
virus-infected adherent and nonadherent cells (Fig. 2). These
results are in agreement with those from analyses of biologi-
cally active IFNs which were shown to be produced in both
adherent and nonadherent cells (Table 1).
Imiquimod does not stimulate expression of IFNA/B and
IL-6 genes in murine monocyte line Raw but alters the NDV-
mediated stimulation of these genes.We have not been able to
induce expression of IFN-a/b genes by imiquimod in any fi-
broblast, B-cell, T-cell, or monocyte line tested (data not
shown). However, we have been able to induce effectively the
expression of various cytokine genes in the murine macro-
phage line Raw 264, both by viral infection and by treatment
with lipopolysaccharide. We have, therefore, tested whether
imiquimod induces expression of IFNA/B and cytokine genes
in these cells. While no stimulation of IFNA, IFNB, or the IL-6
gene could be induced by imiquimod in these cells, treatment
with imiquimod during virus infection significantly inhibited
the Newcastle disease virus (NDV)-mediated induction of
IFNA genes (Fig. 3A). In contrast, treatment with imiquimod
superinduced NDV-induced IFNBmRNA levels by about 2- to
3-fold and IL-6 mRNA levels by about 10-fold. These results
show that, in the absence of detectable stimulation of IFNA/B
and IL-6 genes, imiquimod differentially altered the expression
of IFNA and IFNB or IL-6 genes.
To determine whether these effects can also be seen in cells
where imiquimod induces expression of cytokine genes, PBMC
were infected with NDV in the presence of imiquimod. The
relative levels of IFNA mRNA were lower in cells treated with
both inducers than in those induced with NDV alone. The
presence of IFNA mRNA could also be detected in cells
treated with imiquimod alone (Fig. 3), although the levels were
much lower than those induced by NDV, since maximal levels
of IFNA mRNA in imiquimod-treated cells are induced at 2 h
postinfection (compare Fig. 1). These data indicate that imi-
quimod has a noticeable inhibitory effect on the NDV-stimu-
lated expression of IFNA genes in both human PBMC and the
FIG. 1. Expression of IFN-a/b, TNF-a, IL-6, IL-8, and IRF-1 genes in imi-
quimod-stimulated PBMC. PBMC isolated on a Ficoll gradient were induced (2
3 107 cells per sample) with imiquimod (3 mg/ml) in the presence (1) and
absence (2) of CHX (30 mg/ml) for the indicated times. Isolated total RNA (10
mg) was analyzed by Northern hybridization with the respective probe as de-
scribed in Materials and Methods. As a control, cells were induced with 200
hemagglutinin units of Sendai virus per ml for 4 and 6 h. Films were exposed for
16 h. Hybridization with g-actin probe is shown as a control for RNA loading.
FIG. 2. Expression of IFNA and IFNB genes in induced adherent and non-
adherent PBMC. PBMC were allowed to adhere to plastic for 50 min; nonad-
herent cells were collected, and adherent cells were washed with medium con-
taining 1% fetal bovine serum. Induction was done for 3 h with imiquimod-
stimulated cells (lanes 3 and 8) and for 6 to 7 h with Sendai virus-infected cells
(lanes 5 and 10). Cells treated with CHX alone or CHX in combination with
imiquimod are shown in lanes, 2, 4, 7, and 9. Isolation and analysis of total RNA
were done as described in the legend to Fig. 1. A 16-h exposure of the mem-
branes is shown. Lanes 1 to 5 represent adherent cells, and lanes 6 to 10
represent nonadherent cells. 1, present; 2, absent.
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murine macrophage line Raw. Similar to what was observed
with murine Raw cells, no inhibition in the IFNB and IL-6
mRNAs was seen after treatment with virus and imiquimod
(data not shown). These data suggest that the virus-induced
signal transduction pathways that lead to the induction of
IFNA and IFNB genes are not identical.
Effect of kinase inhibitors on expression of IFN genes. To
determine whether induction of IFNA and IFNB genes by
imiquimod and induction by Sendai virus occur through similar
signal transduction pathways, we analyzed the effects of inhib-
itors of TK, PKC, and protein kinase A (PKA) on stimulation
of IFNA and IFNB gene expression in induced cells. Figure 4
shows that treatment of the cells with staurosporin (PKC in-
hibitor) and genistein (TK inhibitor), before and during induc-
tion, resulted in inhibition of IFNA and IFNB expression, and
no IFNA or IFNB mRNA could be detected in cells 2 h postin-
duction (lanes 4, 6, and 7). Additional experiments in which we
used calphostin C, a more specific inhibitor of PKC, also
showed that pretreatment with 50 nM calphostin C completely
inhibited induction of IFNA (data not shown), thus indicating
that PKC activity is required for the induction process. In
contrast, treatment with HA1004 (PKA inhibitor) did not sig-
nificantly change levels of IFNA and IFNB mRNAs induced by
either Sendai virus or imiquimod (Fig. 4, lanes 5 and 12).
These results suggest that both TK and PKC activity, but not
PKA, are part of the imiquimod-mediated transduction signal.
When the effect of these inhibitors on Sendai virus-mediated
induction of IFNA and IFNB genes was examined, stauro-
sporin and genistein, but not HA1004, were found to inhibit
the appearance of IFNA and IFNB mRNAs in infected cells
(Fig. 4, lanes 11 to 13). However, while staurosporin was able
to completely block induction of IFNA mRNAs, low levels of
IFNA and IFNB mRNAs could still be detected in genistein-
treated cells, suggesting that genistein is a less effective inhib-
itor of virus-mediated induction than is staurosporin.
Similar results were observed when the effect of these inhib-
itors on expression of IL-6, IL-8, and TNF-a genes was exam-
ined (data not shown). Both genistein and staurosporin, but
not HA1004, inhibited the imiquimod- and virus-induced ex-
pression of these genes. In contrast, there was little variation in
the relative levels of actin mRNA induced in the presence and
absence of inhibitors, showing that the effect is specific and is
not due to toxicity or variations in RNA loading. These data,
together with lack of dependence of induction of IFNA and
IFNB genes on cellular protein synthesis, suggest that induc-
tion of IFN genes by both virus infection and imiquimod in-
volves phosphorylation of preexisting cellular factors.
Determination of IFNA subtypes induced by imiquimod.
The high degree of homology among IFNA genes prevents
identification of various IFNA mRNA subtypes by Northern
blot hybridization. We and others have previously used S1 and
RNase protection analyses for identification of various IFNA
mRNAs in infected murine and human cells (29, 35). In the
present study, we used a more sensitive RT-PCR assay. Total
cellular RNA isolated from PBMC induced by imiquimod or
by Sendai virus was used as a template for reverse transcription
of IFNA-specific transcripts. The IFN cDNAs were then am-
plified by PCR, and the amplified DNA was characterized by
restriction analysis, cloned, and sequenced.
Two sets of primers were used for amplification of the
cDNAs (Fig. 5). Initially, primers containing highly conserved
sequences (general primers) were used (see Materials and
Methods) and PCR-amplified DNA fragments were analyzed
by restriction with AvaII and AvaI endonucleases, which are
specific for IFNA1 and IFNA4, respectively. After restriction of
the amplified DNA fragment (369 nt) from both Sendai virus-
and imiquimod-induced cDNAs with AvaII, two small frag-
ments of 171 and 188 bp were detected, indicating the presence
of IFNA1 transcripts in these cells (Fig. 6A). However, the
density of these restriction fragments indicated that the levels
of IFNA1 transcripts in imiquimod-induced cells were much
lower than those in Sendai virus-induced cells. In contrast, the
amplified DNA fragments were not restricted with AvaI, indi-
cating the absence of IFNA4 transcripts in Sendai virus- and
imiquimod-induced cells. The amplified fragment from both
FIG. 3. Imiquimod modulates NDV-mediated induction of IFN and IL-6
genes. Murine Raw 264 cells at 80% confluency and human PBMC were induced
with imiquimod (R) (3 mg/ml) for the indicated periods of time, after which total
RNA was isolated. Alternatively, these cells were induced with NDV (N) (mul-
tiplicity of infection of 5) in the presence and absence of imiquimod (3 mg/ml) for
5 h. Total RNA (10 mg) was analyzed by Northern hybridization as described in
Materials and Methods. A 20-h exposure of the films is shown in panel IFNA (L),
and a 4-h exposure is shown in panel IFNA (S). Cont., control; L, long; S, short.
FIG. 4. Inhibition of imiquimod-mediated induction of IFNA and IFNB
genes by genistein (G) and staurosporin (S). PBMC were pretreated with
genistein (100 nM), staurosporin (80 nM), or HA1004 (H) (30 mM) for 30 min
and then induced with imiquimod or Sendai virus in the presence or absence of
an inhibitor. RNA was isolated at 3 h postinduction with imiquimod (lanes 2 to
9) or at 6 h postinfection with Sendai virus (lanes 10 to 13) and analyzed by
Northern hybridization with IFNA and IFNB probes as described in Materials
and Methods. Hybridization with g-actin probe was used to estimate the amounts
of RNA on filters. 1, present; 2, absent.
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Sendai virus- and imiquimod-induced cDNAs could also be
restricted with HpaI, suggesting the presence of IFNA2mRNA
in induced cells (data not shown).
The amplified fragments were then cloned, and 25 transfor-
mants were selected for sequencing. As shown in Table 3, all
the colonies amplified from the cDNA of Sendai virus-induced
cells were identified as IFNA8, while the clones of amplified
cDNA from imiquimod-induced cells consisted of IFNA8 and
IFNA5. The relative proportions of IFNA8 and IFNA5 were 77
and 23%, respectively. The preferential cloning of the IFNA8
subtype may be due to the 100% homology of the selected
primers with the IFNA8 cDNA. Although the general primer
pair was designed to recognize highly conserved regions of the
IFNA genes, there were small differences in the sequences
corresponding to the primer regions in IFNA1, IFNA2, IFNA6,
IFNA5, and IFNA4 cDNAs (Fig. 5). The conserved 59-end
primer selected shows 100% homology with the IFNA8,
IFNA7, and IFNA5 coding region, while all other correspond-
ing coding regions show a single nucleotide difference. The 39
primers selected show 100% homology with all the IFNA genes
except IFNA5 and IFNA8, which show a single nucleotide
difference.
Although a restriction analysis (with HphI) of the amplified
fragment suggested that IFNA2 mRNA is present in both the
imiquimod- and Sendai virus-induced cells, the IFNA2 clone
was not detected by sequencing. Therefore, we used a second
IFNA2-specific primer pair (Fig. 5) to verify unequivocally the
presence of this subtype. After amplification of cDNA from
imiquimod- and Sendai virus-induced mRNAs, we obtained, as
expected, the 672-bp fragment, which was restricted with Hin-
cII into 550- and 122-nt fragments (Fig. 6B). The presence of
the HincII site in the amplified region is unique to IFNA2.
This 672-nt fragment was then cloned, and 50 colonies were
selected and analyzed by restriction with HincII restriction
endonuclease; all clones but one could be restricted with HincII
and thus were identified as IFNA2. The undigested clone was
identified as IFNA6 by sequencing. All the clones obtained by
cloning of an amplified fragment from Sendai virus-induced
cells were characterized as IFNA2 cDNA by HincII digestion.
The reliability of the analysis with HincII was verified by se-
FIG. 5. General and IFNA2-specific primer sequences present in various human IFNA genes (25). The underlined sequences were used for PCR amplification.
Lowercase letters indicate nucleotides distinct from those in the corresponding region of the primer. The 59 and 39 conserved primers correspond to nt 11067 to 1086
and nt 11415 to 1435, respectively. The IFNA2-specific primers correspond to nt 1911 to 930 (59) and nt 11565 to 1582 (39).
FIG. 6. Restriction analysis of DNA fragments amplified with a general and
an IFNA2-specific set of primers. The RT-PCR was done as described in Mate-
rials and Methods with the end-labelled general and IFNA2-specific primers.
General primers (A) amplified a 369-bp DNA fragment from imiquimod-in-
duced (lanes 1 to 3) and Sendai virus-induced (lanes 4 to 6) cDNAs. Lanes 1 and
4 represent the uncut fragments; restriction with AvaII and the appearance of
two fragments of 171 and 188 bp are shown in lanes 2 and 5. Lanes 3 and 6 show
a lack of restriction with AvaI. The IFNA2-specific primer (B) amplified a 672-nt
DNA fragment (lanes 1 and 3) that was restricted with HincII (lanes 2 and 4).
Lanes 1 and 2 show amplification of a fragment from imiquimod-induced
cDNAs, and lanes 3 and 4 show amplification of a fragment from Sendai virus-
induced cDNAs. The amplified 672-bp fragment and the 171- and 188-bp frag-
ments are marked.
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quencing; sequences of two clones derived from imiquimod-
and Sendai virus-induced samples were identical to IFNA2.
Restriction analysis (Fig. 6B) indicated that a small portion of
the 693-bp fragment was resistant to HincII restriction. This
unrestricted fragment was isolated and cloned. The sequence
analysis showed that this fragment represented IFNA6 in imi-
quimod-induced cells, while it was identical to IFNA2 in Sendai
virus-infected cells. Thus, in summary, this analysis indicates
that whereas imiquimod induces expression of IFNA1, IFNA2,
IFNA5, IFNA6, and IFNA8 in PBMC, in the same cells Sendai
virus infection stimulates expression of IFNA1, IFNA2, and
IFNA8 (Table 3).
Induction of NF-kB-specific binding activity. Since the pro-
moter regions of all the cytokine genes induced by imiquimod
(except for IFNA genes) contain an NF-kB binding site, which
plays a critical role in the inducible expression of these genes,
we examined binding of nuclear proteins from imiquimod-
induced cells and controls to DNA probes corresponding to
the NF-kB sequences present in the HIV-1 LTR (78). Binding
of nuclear proteins from CHX-treated cells and Sendai virus-
infected cells was used as a positive control since both CHX
and virus infection stimulate binding of the p50-p65 complex
(16, 69, 76). Relatively high levels of constitutive nuclear
NF-kB activity were observed in uninduced PBMC, since
NF-kB is constitutively nuclear in mature B cells (54, 69). We
therefore analyzed induced NF-kB binding in separated pri-
mary monocytes. Figure 7 shows the transient increase in the
relative levels of NF-kB-specific complexes (A and B) that
could be detected as early as 25 min after imiquimod induc-
tion, followed by a rapid decrease to basal levels. The forma-
tion of complex A was specific and could be completely inhib-
ited by a 10-fold excess of the unlabelled probe (Fig. 7), while
formation of complex B was slightly inhibited only by a 50-fold
excess of unlabelled probe. In contrast, treatment with CHX
induced a complex with mobility slightly faster than that of
complex A. These data show that imiquimod treatment, similar
to viral infection (16, 76), activates NF-kB-specific binding.
Using antibodies specific to p50, p65, and c-rel, we have dem-
onstrated, by mobility shift assay, the presence of p50 and c-rel
but not p65 in the imiquimod-induced kB complexes (Fig. 7B).
Induction of a4F1-specific binding activity. The A4F1 ele-
ment plays a critical role in the induction of murine IFNA
genes (1), and the transcriptional activation of murine IFNA
genes in virus-infected cells is associated with formation of a
novel complex, A4F1/B (1, 2). Since the consensus of A4F1
sequence is also present in the inducible region (VRE) of
human IFNA genes (Fig. 8C), we examined the binding of
nuclear proteins from imiquimod-treated and virus-infected
cells to DNA probes corresponding to the A4F1 sequence.
In the gel retardation assay, the binding of nuclear proteins
from untreated cells shows the presence of a strong, slowly
moving complex (complex A) and weak, fast-moving com-
plexes (complexes B and C) (Fig. 8A, lane 1). In nuclear
extracts from Sendai virus-infected cells or imiquimod-treated
cells, a significant enhancement of complex B formation was
detected (Fig. 8A, lanes 2, 3, 6, and 7). The formation of this
complex was transient: enhancement was detected as early as
30 min after virus infection or imiquimod treatment (data not
shown), and the levels of the A4F1/B complex returned to
basic levels at 3 to 4 h postinduction. The formation of the
A4F1/B complex was specific; it could be inhibited either with
the unlabelled A4F1 probe or with the 35-nt-long inducible
element (A4IE) of the IFNA4 promoter region that contains
the A4F1 sequence (Fig. 8B) but not with a nonspecific DNA
such as pGEM plasmid or NF-kB probe (data not shown). The
unlabelled A4F1 fragment also inhibited the formation of com-
plex C, present in both the induced and uninduced nuclear
proteins, but not complex A. In contrast, unlabelled A4IE
effectively inhibited the formation of all complexes (A, B, and
C). These results suggest that, similar to what occurs with
murine cells (2), the formation of complex B is related to
transcriptional activation of IFNA genes and that a similar
complex(es) is induced in Sendai virus-infected and imi-
quimod-treated cells. However, it is unlikely that complex B
FIG. 7. Induction of NF-kB binding activities in imiquimod-induced mono-
cytes. Monocytes were prepared from the adherent fraction of PBMC. Nuclear
extracts were prepared as described in Materials and Methods from imiquimod-
treated (3 mg/ml) cells at different times postinduction and analyzed for the
presence of NF-kB activity by using oligonucleotides corresponding to the HIV-1
LTR NF-kB site (see Materials and Methods). All reaction mixtures contained
1 mg of a nonspecific competitor, poly(dI) z poly(dC). (A) The unlabelled probe
was used as a specific competitor at 5- and 50-fold molar excesses. CHX-treated
and uninduced cells were used as controls. (B) A supershift experiment with the
indicated antibodies was done as described in Materials and Methods. 1,
present; 2, absent; S, supershift.
TABLE 3. IFNA subtypes expressed in imiquimod- and Sendai virus-stimulated PBMC
Stimulation
Resulta for:
IFNA1 IFNA13 IFNA2 IFNA4 IFNA5 IFNA6 IFNA7 IFNA8 IFNA14
Sendai virus 1b — 1b,c — — — — 1d —
Imiquimod 1b — 1b,c — 1d 1c — 1d —
a—, not detected; 1, present.
b Determined by restriction analysis of the IFN cDNA amplified by using general primers.
c Determined by restriction analysis and cloning of the IFN cDNA amplified with IFNA2-specific primers.
d Determined by cloning and sequencing of the IFN cDNA amplified with general primers.
VOL. 15, 1995 CYTOKINE INDUCTION BY IMIQUIMOD 2213
represents binding of IRF-1 or NF-kB-specific proteins, since
it could be supershifted neither with IRF-1-, p50-, p65-, nor
c-rel-specific antibodies (data not shown).
Characterization of proteins binding to A4F1 by UV cross-
linking. We have previously shown (2) that, in murine cells
induced with virus, the A4F1/B complex contains at least two
DNA-binding proteins, p96 and p68, but not the IRF-1 pro-
tein. To analyze the proteins binding to the A4F1 probe in
Sendai virus-infected and imiquimod-treated PBMC, nuclear
extracts prepared from Sendai virus-infected or imiquimod-
treated cells at 1 h posttreatment were incubated with the
BrdUrd-substituted A4IE probe. We used this probe rather
than the A4F1 probe because the BrdUrd substitution in A4F1
altered the mobility of A4F1/B and A4F1/C complexes. The
DNA-protein complexes were separated on nondenaturing
gels (Fig. 9A) and UV cross-linked in situ, and the three
complexes detected were individually eluted and subsequently
analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 9B).
While in uninduced cells we detected predominantly com-
plex C, nuclear extracts from both Sendai virus-infected and
imiquimod-induced cells showed a significant enhancement in
formation of complexes A and B (Fig. 9A). Both of these
complexes were efficiently inhibited with unlabelled A4IE oli-
gonucleotides (data not shown). Cross-linking of the A4IE/A
complex shows the presence of two DNA-protein adducts of 96
and 45 kDa present in both induced and uninduced cells (Fig.
7B). However, the A4IE/A complex from uninduced cells
shows an additional DNA-protein adduct of about 55 kDa that
is absent in induced cells. The A4IE/B complex shows the
presence of 29- and 25-kDa DNA-protein adducts in both
induced and uninduced cells (Fig. 9B). The fast-moving com-
plex, A4IE/C, contains three DNA-protein adducts of 45, 29,
and 25 kDa in induced cells, while in uninduced cells, only 29-
and 25-kDa adducts were detected. The 28- and 25-kDa pro-
teins are present in both induced and uninduced cells; how-
ever, the levels of the 29-kDa DNA-protein adduct detected in
induced cells were much higher than those in uninduced cells,
indicating that induction increased DNA binding of the 29-
kDa protein. Thus, these data show that induction by Sendai
virus or imiquimod results in (i) disappearance of binding of
the 55-kDa protein to A4IE and (ii) increased binding of a
29-kDa protein. To determine whether the p55 and p29
FIG. 8. Imiquimod activation of nuclear complex binding to the A4F1
(a4F1) site. Nuclear extracts were prepared from PBMC induced for different
times in the presence of imiquimod or Sendai virus and incubated with a 32P-
labelled A4F1 probe. Protein-DNA complexes were analyzed on a nondenatur-
ing gel as described in Materials and Methods. (A) Kinetics of formation of
induction-specific A4F1 protein complex (A4F1/B). Lane 8 shows mobility of the
probe alone, and lane 1 represents the complexes formed with extracts from the
untreated cells. (B) Inhibition of A4F1/B complex formation. The 32P-labelled
A4F1 probe was preincubated for 15 min with nuclear extracts isolated from cells
treated with imiquimod for 1 h, and then the indicated competitors were added
in various molar excesses. a4F1 and A4IE represent the A4F1 sequence and
VRE present in the murine IFNA4 gene promoter region (2), and pGEM4
plasmid was used as a nonspecific DNA competitor. (C) Comparison of A4F1
binding sites in the VREs of murine and human IFNA promoters. r, purine
residue; y, pyrimidine residue; 1, present; 2, absent.
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present in the uninduced cells represent IRF-2 and its proteo-
lytic product (8, 57), we used the IRF-2 antibodies to analyze
the presence of IRF-2 in the A4IE complexes. However, the
IRF-2 antibodies did not supershift any of the A4IE complexes,
nor did preabsorption of the extracts with these antibodies re-
move the p55 or p29 DNA-protein adduct (data not shown).
Imiquimod does not stimulate the appearance of new PRDI
binding complexes. Virus-mediated induction of IFN genes
has been associated with the induction of binding IRF-1 to
PRDI. The same region can also bind IRF-2, which can repress
IRF-1 activity (22). Induction-specific complexes PRDI-BFi
and TH3 have been shown to contain cleaved IRF-2 or a
14-kDa N-terminal fragment of IRF-2 (8, 57). To determine
whether imiquimod induces PRDI-specific binding, nuclear
extracts from uninduced and imiquimod-induced cells were
incubated with PRDI probe and DNA-protein complexes
formed were analyzed by a gel retardation assay. Two DNA-
protein complexes (A and B) were detected with extracts from
uninduced cells (Fig. 10). These complexes were also observed
after treatment with imiquimod; however, a small, transient
increase in complex A formation was observed at the early
stages of induction. The binding of complex A was easily in-
hibited by the unlabelled PRDI, while the decrease in binding
of complex B required at least a 50-fold excess of the unla-
belled probe. The unlabelled NF-kB probe did not complete
the formation of these two complexes when used in a 5-fold
excess, while a 50-fold excess decreased binding of both of
these complexes. These results indicate the PRDI-specific
binding of complex A. The identities of the proteins present in
these complexes were examined by testing the abilities of var-
ious antibodies to modulate their formation. However, anti-
serum to neither IRF-1 nor IRF-2 could abolish formation of
complex A or B (when added before formation of the complexes)
or supershift these complexes (when added after complex forma-
tion) (data not shown). Since these antibodies were shown to
interact with IRF-1 and IRF-2 on Western blot (immunoblot)
analysis and by a supershift assay (27a), these data suggest that
complexes A and B do not contain either IRF-1 or IRF-2.
DISCUSSION
We have shown in this study that imiquimod induces in
PBMC expression of IFNA/B genes and cytokine genes, includ-
ing IL-6, IL-8, and TNF-a genes. In contrast to viral infection,
which effectively induces IFN genes in a large variety of pri-
mary cells and established cell lines, imiquimod was able to
induce these genes only in primary human monocytes or in
mouse spleen cells, and not in established lines of fibroblasts,
B cells, or monocytes. Moreover, occasionally some PBMC did
not respond to imiquimod stimulation and no IFN synthesis
could be detected. The reasons for this unresponsiveness are
presently unknown.
Induction of IFN and cytokine genes by imiquimod is tran-
sient and does not require cellular protein synthesis, indicating
FIG. 9. UV cross-linking analysis of DNA-protein adduct formed between the IE sequence and nuclear extracts from imiquimod-treated and Sendai virus-infected
cells. (A) Nuclear extracts prepared from induced cells at 1 and 3 h postinduction and from uninduced controls were incubated with the BrdUrd-substituted A4IE probe
and resolved on a 4% acrylamide gel. (B) DNA and proteins were UV cross-linked in situ; gels were UV irradiated as described previously (78); bands corresponding
to the A, B, and C complexes were eluted; and protein-DNA complexes were analyzed on an SDS–10% polyacrylamide gel. The molecular mass (MW) markers and
the p55 and p29 DNA-protein adducts are indicated.
VOL. 15, 1995 CYTOKINE INDUCTION BY IMIQUIMOD 2215
that imiquimod, similar to viral infection, modifies or activates
preexisting latent cellular factors. The fact that induction of
IFNA and IFNB genes by these two inducers requires TK and
PKC activity further emphasizes the importance of protein
phosphorylation in the induction of these genes. The fact that
virus and imiquimod induce similar sets of cytokine genes
indicates that activation may involve a common cis element(s)
conserved in the promoter regions of all these cytokine genes,
such as an NF-kB binding site preserved in the promoter
regions of all genes examined, except the IFNA genes. Stimu-
lated transcription of the TNF-a gene was shown to involve
interaction between NF-kB and AP-1 binding proteins, and
transcription of IL-6 and IL-8 genes required interaction syn-
ergism between NF-IL6 and NF-kB (38, 44, 52); transcrip-
tional activation of the IFNB gene depends on interaction
between IRF-1, ATF-2, HMGI(Y), and the NF-kB complex
(10, 75). Our data showed enhancement of NF-kB-specific
binding in imiquimod-treated primary monocytes and suggest
that NF-kB-specific binding may be required for the imi-
quimod-mediated activation of IFNB, TNF-a, IL-6, and IL-8
genes. Interestingly, imiquimod induced expression of the IL-8
gene more efficiently than did viral infection. It was recently
shown that the NF-kB-like site in the IL-8 promoter region is
activated by the c-rel/p65 complex (38), suggesting that the
NF-kB-specific proteins induced by Sendai virus and imi-
quimod in PBMC may not be identical. Indeed, we have shown
in this study the presence of p50 and c-rel in the imiquimod-
induced NF-kB complexes, while virus infection was shown to
predominantly activate the binding of the p50-p65 complex (76).
To analyze further the effect of imiquimod stimulation on
the expression of IFNA genes, we identified the individual
IFNA genes expressed in imiquimod-stimulated PBMC and
compared them with Sendai virus-induced IFNA genes in these
cells. It was previously shown (18, 29) that IFNA1 and IFNA2
are the major mRNAs present in virus-induced leukocytes,
while IFNA8, IFNA4, IFNA5, IFNA7, IFNA14, IFNA21, and
IFNA16 mRNAs were identified as minor components. By
PCR amplification and cloning, we detected IFNA1, IFNA2,
and IFNA8 in Sendai virus-induced human leukocytes. Under
the same experimental conditions, IFNA1, IFNA2, IFNA8,
IFNA5, and IFNA6 were detected in imiquimod-induced
PBMC. Although we cannot completely eliminate the possibil-
ity that another minor IFNAmRNA is present either in Sendai
virus- or imiquimod-induced cells, these results indicate a
higher degree of IFNA mRNA subtype heterogenicity in imi-
quimod-induced PBMC than in Sendai virus-infected cells.
The region (VRE) required for maximal inducibility of the
human IFNA1 and IFNB genes contains sets of GAAAGT and
GAAATG repeats (14, 47, 48) that are also preserved in the
inducible region of the murine IFNA gene promoters (58).
When multimerized, these repeats serve as the binding site for
IRF-1 and IRF-2 (22, 47), and IRF-1 was shown to activate
these sequences in the yeast system (67) as well as in a tran-
sient expression assay (1). Nevertheless, our analysis did not
show a significant increase in IRF-1-specific binding in imi-
quimod-treated PBMC. A virus-inducible, 35-nt sequence
identified in a promoter of the murine IFNA4 gene contains a
symmetric sequence, GTAAAGAAAGT (A4F1), essential for
the induction of the IFNA4 promoter (2), that partially over-
laps the putative IRF-1 binding site. This sequence is well
preserved in the inducible region of murine and human IFNA
genes, including those induced by imiquimod (Fig. 8C). In this
study, we have shown that induction of IFNA genes in virus-
infected and imiquimod-treated cells is associated with an in-
duction-specific complex (A4F1/B) formed between the A4F1
sequence and nuclear extract from induced cells. The mobility
of this complex could not be supershifted with either anti-
IRF-1 or anti-IRF-2 antibodies or anti-STAT p91 antibodies
(data not shown). The UV cross-linking analysis showed that at
least four nuclear proteins bind to the 35-nt VRE. While the
majority of DNA-protein adducts were identified in both in-
duced and uninduced cells, two major differences in the bind-
ing profiles were observed. First, extracts from the control
cells, but not from induced cells, show the presence of a 55-
kDa protein that corresponds in size to the proteins of the
IRF-1 family. The down-regulation of expression of IFNA and
IFNB promoter regions by IRF-2 has been well documented in
cotransfection experiments. Although the binding of IRF-2 to
the inducible element could contribute to the negative regula-
tion of this promoter (22, 23), we have not detected the pres-
ence of IRF-2 in the AF-1 complexes. Another PRDI zinc
family binding protein has been shown to function as a repres-
sor in cotransfection experiments (80); however, this protein is
88 kDa and therefore differs from the 55-kDa protein identi-
fied in the present study. The second difference is the increase
in the relative levels of the 28-kDa DNA-protein adduct in
induced cells, suggesting an increase in binding capacity or a
more efficient cross-linking of the 28-kDa protein in induced
cells. The possibility that this protein represents a processed
form of IRF-2 (8, 57) cannot be eliminated, since the antibod-
ies against IRF-2 used do not recognize the N-terminal region
of this protein. These results, however, indicate that, similar to
what has been observed with the murine system (2), the for-
mation of an induction-specific complex B is not the result of
binding of a novel protein to the inducible region but rather is
the result of posttranslational modifications of the constitu-
tively expressed binding proteins or their interaction with an-
other non-DNA-binding component of the transcriptional
FIG. 10. Imiquimod does not stimulate PRDI-specific binding activity. Nu-
clear extracts prepared from imiquimod-induced cells and uninduced controls
were incubated with 32P-labelled PRDI probe, and the DNA-protein complexes
were analyzed by a gel shift assay. Competition for complex formation was done
with the unlabelled PRDI and NF-kB probes at 5- and 50-fold excesses.
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complex. Since the formation of the A4F1/B complex is abol-
ished in the presence of TK and PKC inhibitors (data not
shown), we suggest that imiquimod-induced phosphorylation
of the preexisting A4F1 binding proteins is an essential step in
the induction process.
The similarity between Sendai virus- and imiquimod-in-
duced expression of IFN and cytokine genes may come as a
major surprise to researchers in the IFN field. The require-
ment for dsRNA has been extensively documented for infec-
tions with a large variety of viruses (50). The present data
suggest that activation by both these inducers involves phos-
phorylation rather than the presence of dsRNA per se. Phos-
phorylation was shown to play a role both in the dissociation or
degradation of IkB complexes, leading to translocation of the
NF-kB1 complex to the nucleus (5, 17), and in the activation of
IRF-1 (79).
Recently, it has been shown that IFNs activate tyrosine ki-
nases of the Jak family (9). These kinases directly phosphory-
late proteins Stat91 and Stat113, which are part of the ISGF-3
complex that binds to the IFN-responsive element (ISRE) of
the IFN-activated genes and activates transcription of these
genes (31, 66). We have shown (63) that a priming with IFN
(73) enhances virus-induced expression of IFN-a/b, as well as
the other cytokines, e.g., IL-6 and TNF-a. Accordingly, prim-
ing with IFN enhanced imiquimod-stimulated expression of
IFNA and IFNB genes (data not shown). It is likely, therefore,
that IFN provides a costimulation signal both in the imi-
quimod- and virus-induced phosphorylation pathways. Activa-
tion of a signal transduction by a synthetic ligand able to
aggregate membrane receptors was used to study the T-cell
receptor-mediated signalling pathway (72). The membrane-
permeable imiquimod may, therefore, function as a ligand,
alter intramembrane interactions, and initiate intracellular sig-
nalling. Furthermore, the direct binding of pyridinyl-imidazole
compounds to mitogen-activated protein kinase (CSBP) with a
consequent inhibition of kinase activity reported recently (41)
raises the possibility that imiquimod interacts directly with a
kinase modulating the transduction pathway leading to the
transcriptional activation of the cytokine genes.
The fact that imiquimod inhibits virus-mediated induction of
IFNA genes while it superinduces induction of IFNB and IL-6
genes indicates that induction of IFNA may proceed by a path-
way distinct from that for the other cytokines examined and
adds to the complexity of both the pleiotropic effects of these
inducers and the mechanisms by which these genes are acti-
vated. Finally, the use of imiquimod and its analogs may pro-
vide a useful tool for dissecting the role of kinase pathways in
the virus-mediated signal transduction inducing inflammatory
cytokines.
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